English
新闻公告
More
化学进展 2013, Vol. 25 Issue (09): 1588-1593 DOI: 10.7536/PC130714 前一篇   后一篇

• 癌症化学预防专辑 •

抗肿瘤疫苗的研究进展

陈继冰, 袁远英, 徐克成*   

  1. 暨南大学医学院附属复大肿瘤医院 广州510665
  • 收稿日期:2012-12-01 修回日期:2013-06-01 出版日期:2013-09-25 发布日期:2013-07-31
  • 通讯作者: 徐克成 E-mail:xukc@vip.163.com

Research Progress of Anti-Cancer Vaccine

Chen Jibing, Yuan Yuanying, Xu Kecheng*   

  1. Fuda Hospital, School of Medicine, Jinan University, Guangzhou 510665, China
  • Received:2012-12-01 Revised:2013-06-01 Online:2013-09-25 Published:2013-07-31

长期以来,肿瘤和免疫学治疗癌症的目标是激活免疫系统。在经历了几十年的失望之后,最近在临床试验中找到了循证医学方面的证据,癌症治疗的高潮终于到来。最值得一提的是抗 CTLA4 抗体(即ipilimumab),可成功地大幅度增加那些常规治疗失败的转移性黑色素瘤患者的生存时间。本文回顾了免疫耐受、免疫功能和免疫抑制在调节抗肿瘤免疫应答中的作用,介绍了新近出现的靶向治疗的研究,并指出免疫疗法为在癌症患者体内获得持久免疫反应开启了一条新途径。

Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable is the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.

Contents
1 Introduction
2 Cancer vaccines are finally showing early signals of activity
3 An efficacious cell-based vaccine for prostate cancer
4 Combination immunotherapy
5 Recalling the use of vaccines
6 Perspective

中图分类号: 

()

[1] Dougan M, Dranoff G. Annu. Rev. Immunol., 2009, 27: 83—117
[2] Hall S S. A Commotion in the Blood: Life, Death, and the Immune System. New York: Henry Holt and Company, 1997
[3] Sylvester R J. International Journal of Urology, 2011, 18: 113—120
[4] Palucka K, Banchereau J, Mellman I. Immunity, 2010, 33: 464—478
[5] Boon T, Coulie P G, Van den Eynde B J, van der Bruggen P. Annu. Rev. Immunol., 2006, 24: 175—208
[6] Zhang L, Conejo-Garcia J R, Katsaros D, Gimotty P A, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman M N, Rubin S C, Coukos G. N. Engl. J. Med., 2003, 348: 203—213
[7] Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc P H, Trajanoski Z, Fridman W H, Pages F. Science, 2006, 313: 1960—1964
[8] Rosenberg S A, Yang J C, Restifo N P. Nat. Med., 2004, 10: 909—915
[9] Schwartzentruber D J, Lawson D H, Richards J M, Conry R M, Miller D M, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra K L, White R L, Gonzalez R, Kuzel T M, Curti B, Leming P D, Whitman E D, Balkissoon J, Reintgen D S, Kaufman H, Marincola F M, Merino M J, Rosenberg S A, Choyke P, Vena D, Hwu P. N. Engl. J. Med., 2011, 364: 2119—2127
[10] Kenter G G, Welters M J, Valentijn A R, Lowik M J, Berends-van der Meer D M, Vloon A P, Essahsah F, Fathers L M, Offringa R, Drijfhout J W, Wafelman A R, Oostendorp J, Fleuren G J, van der Burg S H, Melief C J. N. Engl. J. Med., 2009, 361: 1838—1847
[11] Leffers N, Lambeck A J, Gooden M J, Hoogeboom B N, Wolf R, Hamming I E, Hepkema B G, Willemse P H, Molmans B H, Hollema H, Drijfhout J W, Sluiter W J, Valentijn A R, Fathers L M, Oostendorp J, van der Zee A G, Melief C J, van der Burg S H, Daemen T, Nijman H W. Int. J. Cancer, 2009, 125: 2104—2113
[12] Vansteenkiste J, Zielinksi M, Linder A, Dahabre J, Esteban E, Malinowski W, Jassem J, Passlick B, Lehmann F, Brichard V G. J. Thorac. Oncol., 2007, 2(8): S334—S335
[13] Freedman A, Neelapu S S, Nichols C, Robertson M J, Djulbegovic B, Winter J N, Bender J F, Gold D P, Ghalie R G, Stewart M E, Esquibel V, Hamlin P. J. Clin. Oncol., 2009, 27: 3036—3043
[14] Kantoff P W, Schuetz T J, Blumenstein B A, Glode L M, Bilhartz D L, Wyand M, Manson K, Panicali D L, Laus R, Schlom J, Dahut W L, Arlen P M, Gulley J L, Godfrey W R. J. Clin. Oncol., 2010, 28: 1099—1105
[15] Neller M A, Lopez J A, Schmidt C W. Seminars in Immunology, 2008, 20: 286—295
[16] Copier J, Dalgleish A. Current Opinion in Molecular Therapeutics, 2010, 12: 14—20
[17] Schuler G. Eur. J. Immunol., 2010, 40: 2123—2130
[18] Cheever M A, Schlom J, Weiner L M, Lyerly H K, Disis M L, Greenwood A, Grad O, Nelson W G. Clin. Cancer Res., 2008, 14: 5692—5699
[19] Rammensee H G, Weinschenk T, Gouttefangeas C, Stevanovic S. Immunol. Rev., 2002, 188: 164—176
[20] Small E J, Fratesi P, Reese D M, Strang G, Laus R, Peshwa M V, Valone F H. J. Clin. Oncol., 2000, 18: 3894—3903
[21] Kantoff P W, Higano C S, Shore N D, Berger E R, Small E J, Penson D F, Redfern C H, Ferrari A C, Dreicer R, Sims R B, Xu Y, Frohlich M W, Schellhammer P F. N. Engl. J. Med., 2010, 363: 411—422
[22] Wolchok J D, Hoos A, O'Day S, Weber J S, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi F S. Clin. Cancer Res., 2009, 15: 7412—7420
[23] Leach D R, Krummel M F, Allison J P. Science, 1996, 271: 1734—1736
[24] Hodi F S, Butler M, Oble D A, Seiden M V, Haluska F G, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch M T, Ramaiya N, Chen T C, Neuberg D, Allison J P, Mihm M C, Dranoff G. Proc. Natl. Acad. Sci. U. S. A., 2008, 105: 3005—3010
[25] Chapman P B, Hauschild A, Robert C, Haanen J B, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day S J, Sosman J A, Kirkwood J M, Eggermont A M, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee R J, Flaherty K T, McArthur G A. N. Engl. J. Med., 2011, 364: 2507—2516
[26] Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, Goyal G, Li W, Neuberg D, Blumberg R, Hacohen N, Porter D, Zawel L, Dranoff G. J. Exp. Med., 2010, 207: 2195—2206
[27] Ferrer I R, Wagener M E, Robertson J M, Turner A P, Araki K, Ahmed R, Kirk A D, Larsen C P, Ford M L. J. Immunol., 2010, 185: 2004—2008
[28] Machiels J P, Reilly R T, Emens L A, Ercolini A M, Lei R Y, Weintraub D, Okoye F I, Jaffee E M. Cancer Res., 2001, 61: 3689—3697
[29] Alagkiozidis I, Facciabene A, Tsiatas M, Carpenito C, Benencia F, Adams S, Jonak Z, June C H, Powell D J Jr, Coukos G. J. Transl. Med., 2011, 9: art. no. 77
[30] Obeid M, Tesniere A, Ghiringhelli F, Fimia G M, Apetoh L, Perfettini J L, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Nat. Med., 2007, 13: 54—61
[31] Senzer N N, Kaufman H L, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis J J. J. Clin. Oncol., 2009, 27: 5763—5771
[32] Beatty G L, Chiorean E G, Fishman M P, Saboury B, Teitelbaum U R, Sun W, Huhn R D, Song W, Li D, Sharp L L, Torigian D A, O'Dwyer P J, Vonderheide R H. Science, 2011, 331: 1612—1616
[33] Schreiber R D, Old L J, Smyth M J. Science, 2011, 331: 1565—1570

[1] 顾顺心, 姜琴, 施鹏飞. 发光铱(Ⅲ)配合物抗肿瘤活性研究及应用[J]. 化学进展, 2022, 34(9): 1957-1971.
[2] 冯海弟, 赵璐, 白云峰, 冯锋. 纳米金属有机框架在肿瘤靶向治疗中的应用[J]. 化学进展, 2022, 34(8): 1863-1878.
[3] 陈晓峰, 王开元, 梁芳铭, 姜睿祺, 孙进. 外泌体递药系统及其在肿瘤治疗中的应用[J]. 化学进展, 2022, 34(4): 773-786.
[4] 王嘉莉, 朱凌, 王琛, 雷圣宾, 杨延莲. 循环肿瘤细胞及细胞外囊泡的纳米检测技术[J]. 化学进展, 2022, 34(1): 178-197.
[5] 荆晓东, 孙莹, 于冰, 申有青, 胡浩, 丛海林. 肿瘤微环境响应药物递送系统的设计[J]. 化学进展, 2021, 33(6): 926-941.
[6] 许惠凤, 董永强, 朱希, 余丽双. 新型二维材料MXene在生物医学的应用[J]. 化学进展, 2021, 33(5): 752-766.
[7] 刘加伟, 王婧, 王其, 范曲立, 黄维. 激活型有机光声造影剂的应用[J]. 化学进展, 2021, 33(2): 216-231.
[8] 王欣瑜, 赵富平, 张儒, 孙子茹, 刘胜男, 高清志. 抗肿瘤缺氧诱导因子-1的小分子抑制剂[J]. 化学进展, 2021, 33(12): 2259-2269.
[9] 官启潇, 郭和泽, 窦红静. 细胞膜修饰的纳米载体与肿瘤免疫治疗[J]. 化学进展, 2021, 33(10): 1823-1840.
[10] 郭珊, 周翔. 循环肿瘤细胞体内检测技术及其应用研究[J]. 化学进展, 2021, 33(1): 1-12.
[11] 吴晴, 唐一源, 余淼, 张悦莹, 李杏梅. 基于肿瘤微环境响应的DNA纳米结构递药系统[J]. 化学进展, 2020, 32(7): 927-934.
[12] 孙子茹, 刘胜男, 高清志. 靶向葡萄糖转运蛋白(GLUTs)抗癌药物的开发[J]. 化学进展, 2020, 32(12): 1869-1878.
[13] 宫苗, 王晓英, 王晓宁. 血液肿瘤相关生物标志物的电化学传感检测[J]. 化学进展, 2019, 31(6): 894-905.
[14] 徐子悦, 张运昌, 林佳乐, 王辉, 张丹维, 黎占亭. 药物输送体系构筑中的超分子组装策略[J]. 化学进展, 2019, 31(11): 1540-1549.
[15] 范昭璇, 赵亮, 张学记. 循环肿瘤DNA的检测:从数字化到测序[J]. 化学进展, 2019, 31(10): 1384-1395.
阅读次数
全文


摘要

抗肿瘤疫苗的研究进展